We are proud to have moved from seventh to second place this year in the PatientView survey assessing the corporate reputation of pharmaceutical companies working with oncology patient organizations. We improved our ranking with an uplift of 5 places compared to last year.
We also placed 4th (+4 places) in the ranking for patient organizations familiar with Servier. Our assessment was very positive, particularly with respect to patient centricity, patient communication, ease of working and long-term relationship.
These very good results demonstrate our sustained commitment to working ever more closely with patients and the patient organizations that represent them, specifically in oncology.
“This uplift is a fine reflection of the progress we are making in how we include the patient voice in our activities, in addition to the enduring partnerships we engage in and that increasingly grow in trust over time. I would like to thank all our teams for their contributions, as well as the patient community, of course, for this new stamp of approval.”Bertrand Renaud, Chief Patient Officer
2nd out of 23
among patient organizations who work with pharmaceutical groups in oncology (+5 places)
4th out of 24
among patient organizations familiar with pharmaceutical groups in oncology (+4 places)
of patient organizations working with Servier
“These results demonstrate and illustrate our commitment to establishing strong ties and long-term partnerships with the patient community at every stage of their experience. We extend a hearty thanks to all patient organizations and Servier teams involved for their contributions to obtaining these fantastic results.”Delphine Nicolas, Head of Global Patients Relations for Servier
The 2022 PatientView “Cancer Edition” survey was conducted among 555 patient organizations located all around world. Its results are reported for 24 pharmaceutical groups.
The SHAPE example: how therapeutic support is co-constructed with patients
As part of the SHAPE program1, in collaboration with the DiCE patient organization (Digestive Cancers Europe) supporting people with gastrointestinal cancer, we launched a group-wide call for innovative proposals in 2021-2022. Our aim was to enable Group subsidiaries to deploy and pilot a local initiative co-constructed with patients. Winners include the HeartburnCancer.net website from our British subsidiary and “Don’t let cancer disrupt your life.We are here to help you,” an initiative from our Lithuanian subsidiary that trains former patients to support current patients and their families.
 Support Harmonized Advances for better Patient Experiences